MedTrace Logo

Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD

NCT05644717 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2025-03-21

No results posted yet for this study

Summary

Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)

Conditions

  • Liver Fat
  • Liver Fibrosis
  • Glycemic Control
  • Body Weight Changes
  • Waist Circumference
  • Tolerance

Interventions

DRUG

Ertugliflozin 5 mg, 15mg

Ertugliflozin 5/15mg once daily in addition to standard of care

Sponsors & Collaborators

  • Getz Pharma

    lead INDUSTRY

Principal Investigators

  • Umar Raja, MBBS · Shifa International Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-11-01
Completion
2025-12-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05644717 on ClinicalTrials.gov